Creating a new type of radiotherapy that delivers high doses quickly to treat cancer
Development of an ultra-high dose rate rotational linac for FLASH Radiotherapy
This study is exploring a new type of cancer treatment called FLASH radiotherapy, which aims to deliver radiation more quickly and accurately to tumors while protecting healthy tissue, potentially offering better outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11046540 on NIH RePORTER |
What this research studies
This research focuses on developing an innovative radiotherapy system that can deliver ultra-high dose rates, known as FLASH radiotherapy, to improve cancer treatment outcomes. By utilizing advanced technologies, the project aims to enhance the precision of radiation delivery while minimizing damage to surrounding healthy tissues. The approach involves overcoming significant technical challenges to create a linear accelerator capable of producing high dose rates, which could lead to more effective tumor control. Patients may benefit from this new treatment method if it proves successful in clinical applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who require radiotherapy and may benefit from improved treatment methods.
Not a fit: Patients who are not undergoing radiotherapy or those with conditions that do not respond to radiation treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with reduced side effects for patients.
How similar studies have performed: Other research has shown promise in using high dose rate techniques for radiotherapy, but this specific approach is innovative and aims to address existing limitations.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Sheng, Ke — University of California, San Francisco
- Study coordinator: Sheng, Ke
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.